Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Gross Margin (2016 - 2025)

BioCorRx's Gross Margin history spans 15 years, with the latest figure at 100.0% for Q1 2025.

  • For Q1 2025, Gross Margin rose 4605.0% year-over-year to 100.0%; the TTM value through Mar 2025 reached 100.0%, up 5537.0%, while the annual FY2024 figure was 78.25%, 1861.0% up from the prior year.
  • Gross Margin for Q1 2025 was 100.0% at BioCorRx, roughly flat from 100.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q2 2024 and bottomed at 31.08% in Q4 2023.
  • The 5-year median for Gross Margin is 88.41% (2021), against an average of 79.19%.
  • The largest annual shift saw Gross Margin surged 11244bps in 2021 before it crashed -5846bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 82.14% in 2021, then increased by 9bps to 89.53% in 2022, then crashed by -65bps to 31.08% in 2023, then soared by 222bps to 100.0% in 2024, then changed by 0bps to 100.0% in 2025.
  • Per Business Quant, the three most recent readings for BICX's Gross Margin are 100.0% (Q1 2025), 100.0% (Q2 2024), and 53.95% (Q1 2024).